Outgoing Senate Finance Committee Chairman Orrin HatchOrrin Grant HatchCongress, stop holding 'Dreamers' hostage Drug prices are declining amid inflation fears The national action imperative to achieve 30 by 30 MORE (R-Utah) wrote a letter to GOP colleagues on Wednesday urging them to oppose a proposal from President TrumpDonald TrumpCapitol fencing starts coming down after 'Justice for J6' rally Netanyahu suggests Biden fell asleep in meeting with Israeli PM Aides try to keep Biden away from unscripted events or long interviews, book claims MORE to lower drug prices.
Hatch’s letter, obtained by The Hill, is an illustration of the divide among Republicans over proposals to lower drug prices, with some Republican lawmakers breaking with Trump.
Hatch’s letter, sent to other Republican senators on the Finance Committee, warns Trump’s proposal would “dampen research and development---depriving patients of future treatment breakthroughs and further eroding necessary competition.”
Drug companies are also fiercely opposed to Trump’s proposal, warning it would harm innovation.
Hatch had in recent weeks discussed the possibility of organizing a letter from multiple GOP senators with concerns about the proposal, sources said. But the Trump administration lobbied GOP senators to hold off on publicly criticizing the proposal, an effort first reported by Politico. Hatch’s letter sent Wednesday is only signed by him, not other GOP senators.
Still, the Trump administration faces headwinds in moving forward with the proposal. Sen. Chuck GrassleyChuck GrassleyGrassley calls for federal prosecutor to probe botched FBI Nassar investigation Woman allegedly abused by Nassar after he was reported to FBI: 'I should not be here' Democrat rips Justice for not appearing at US gymnastics hearing MORE (R-Iowa), the incoming chairman of the Finance Committee, has also criticized the idea. A Grassley spokesperson earlier this month warned the plan would impose “price controls.”
Hatch said drug prices do need to be lower, but warned colleagues that "free-market principles" are "vastly superior to importing international price controls into the Medicare program."
The Trump administration defends its proposal by arguing Medicare currently pays essentially whatever price drug companies want for certain drugs, and that system needs to change.
Hatch criticizes not only the proposal but also the authority it is based on, known as the Center for Medicare and Medicaid Innovation, which was created by the Affordable Care Act. Hatch warns that center can have too much power to make changes to Medicare without congressional approval.